vs
Steris（STE）与天宝（TRMB）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是天宝的1.5倍（$1.5B vs $969.8M），天宝净利率更高（16.1% vs 12.9%，领先3.3%），Steris同比增速更快（9.2% vs -73.7%），天宝自由现金流更多（$360.9M vs $199.5M），过去两年Steris的营收复合增速更高（15.8% vs 0.9%）
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
天宝（Trimble Inc.）是1978年成立的美国科技企业，总部位于科罗拉多州威斯敏斯特，于纳斯达克上市，为标普500成分股。公司面向建筑工程、地理空间测绘、交通物流等多个行业，提供软硬件产品及相关技术服务。
STE vs TRMB — 直观对比
营收规模更大
STE
是对方的1.5倍
$969.8M
营收增速更快
STE
高出82.8%
-73.7%
净利率更高
TRMB
高出3.3%
12.9%
自由现金流更多
TRMB
多$161.4M
$199.5M
两年增速更快
STE
近两年复合增速
0.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $969.8M |
| 净利润 | $192.9M | $156.6M |
| 毛利率 | 43.8% | 72.0% |
| 营业利润率 | 18.3% | 22.3% |
| 净利率 | 12.9% | 16.1% |
| 营收同比 | 9.2% | -73.7% |
| 净利润同比 | 11.2% | 73.6% |
| 每股收益（稀释后） | $1.96 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STETRMB
| Q4 25 | $1.5B | $901.2M | ||
| Q3 25 | $1.5B | $875.7M | ||
| Q2 25 | $1.4B | $840.6M | ||
| Q1 25 | $1.5B | $983.4M | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.3B | $875.8M | ||
| Q2 24 | $1.3B | $870.8M | ||
| Q1 24 | $1.1B | $953.3M |
净利润STETRMB
| Q4 25 | $192.9M | $111.5M | ||
| Q3 25 | $191.9M | $89.2M | ||
| Q2 25 | $177.4M | $66.7M | ||
| Q1 25 | $145.7M | $90.2M | ||
| Q4 24 | $173.5M | — | ||
| Q3 24 | $150.0M | $40.6M | ||
| Q2 24 | $145.4M | $1.3B | ||
| Q1 24 | $-1.4M | $57.2M |
毛利率STETRMB
| Q4 25 | 43.8% | 68.9% | ||
| Q3 25 | 44.2% | 68.3% | ||
| Q2 25 | 45.1% | 66.7% | ||
| Q1 25 | 43.3% | 69.3% | ||
| Q4 24 | 44.5% | — | ||
| Q3 24 | 43.6% | 65.7% | ||
| Q2 24 | 44.7% | 62.7% | ||
| Q1 24 | 40.2% | 62.3% |
营业利润率STETRMB
| Q4 25 | 18.3% | 16.7% | ||
| Q3 25 | 18.2% | 14.6% | ||
| Q2 25 | 17.7% | 11.6% | ||
| Q1 25 | 14.6% | 17.6% | ||
| Q4 24 | 17.9% | — | ||
| Q3 24 | 16.5% | 13.3% | ||
| Q2 24 | 14.5% | 7.1% | ||
| Q1 24 | 22.0% | 11.5% |
净利率STETRMB
| Q4 25 | 12.9% | 12.4% | ||
| Q3 25 | 13.1% | 10.2% | ||
| Q2 25 | 12.8% | 7.9% | ||
| Q1 25 | 9.8% | 9.2% | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 11.3% | 4.6% | ||
| Q2 24 | 11.4% | 151.2% | ||
| Q1 24 | -0.1% | 6.0% |
每股收益（稀释后）STETRMB
| Q4 25 | $1.96 | $0.46 | ||
| Q3 25 | $1.94 | $0.37 | ||
| Q2 25 | $1.79 | $0.27 | ||
| Q1 25 | $1.48 | $0.36 | ||
| Q4 24 | $1.75 | — | ||
| Q3 24 | $1.51 | $0.16 | ||
| Q2 24 | $1.46 | $5.34 | ||
| Q1 24 | $-0.02 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $423.7M | $253.4M |
| 总债务越低越好 | $1.9B | $1.4B |
| 股东权益账面价值 | $7.2B | $5.8B |
| 总资产 | $10.6B | $9.3B |
| 负债/权益比越低杠杆越低 | 0.27× | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资STETRMB
| Q4 25 | $423.7M | $232.7M | ||
| Q3 25 | $319.2M | $265.9M | ||
| Q2 25 | $279.7M | $290.0M | ||
| Q1 25 | $171.7M | $738.8M | ||
| Q4 24 | $155.2M | — | ||
| Q3 24 | $172.2M | $1.0B | ||
| Q2 24 | $198.3M | $944.1M | ||
| Q1 24 | $207.0M | $255.1M |
总债务STETRMB
| Q4 25 | $1.9B | $1.4B | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | $1.4B | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $3.1B | — |
股东权益STETRMB
| Q4 25 | $7.2B | $5.8B | ||
| Q3 25 | $7.0B | $5.7B | ||
| Q2 25 | $7.0B | $5.4B | ||
| Q1 25 | $6.6B | $5.7B | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $6.6B | $5.9B | ||
| Q2 24 | $6.4B | $5.6B | ||
| Q1 24 | $6.3B | $4.3B |
总资产STETRMB
| Q4 25 | $10.6B | $9.0B | ||
| Q3 25 | $10.4B | $9.1B | ||
| Q2 25 | $10.4B | $8.9B | ||
| Q1 25 | $10.1B | $9.5B | ||
| Q4 24 | $10.0B | — | ||
| Q3 24 | $10.2B | $9.9B | ||
| Q2 24 | $10.1B | $9.6B | ||
| Q1 24 | $11.1B | $9.3B |
负债/权益比STETRMB
| Q4 25 | 0.27× | 0.24× | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.29× | 0.24× | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.50× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $298.2M | $386.2M |
| 自由现金流经营现金流 - 资本支出 | $199.5M | $360.9M |
| 自由现金流率自由现金流/营收 | 13.3% | 37.2% |
| 资本支出强度资本支出/营收 | 6.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.55× | 2.47× |
| 过去12个月自由现金流最近4个季度 | $917.1M | — |
8季度趋势，按日历期对齐
经营现金流STETRMB
| Q4 25 | $298.2M | — | ||
| Q3 25 | $287.8M | $123.8M | ||
| Q2 25 | $420.0M | $155.6M | ||
| Q1 25 | $260.8M | $115.1M | ||
| Q4 24 | $332.8M | — | ||
| Q3 24 | $250.7M | $94.9M | ||
| Q2 24 | $303.7M | $87.6M | ||
| Q1 24 | $254.8M | $233.8M |
自由现金流STETRMB
| Q4 25 | $199.5M | — | ||
| Q3 25 | $201.3M | $116.6M | ||
| Q2 25 | $326.4M | $149.0M | ||
| Q1 25 | $189.9M | $109.0M | ||
| Q4 24 | $243.6M | — | ||
| Q3 24 | $148.8M | $88.5M | ||
| Q2 24 | $195.7M | $73.3M | ||
| Q1 24 | $163.3M | $227.0M |
自由现金流率STETRMB
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.8% | 13.3% | ||
| Q2 25 | 23.5% | 17.7% | ||
| Q1 25 | 12.8% | 11.1% | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 11.2% | 10.1% | ||
| Q2 24 | 15.3% | 8.4% | ||
| Q1 24 | 14.6% | 23.8% |
资本支出强度STETRMB
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.9% | 0.8% | ||
| Q2 25 | 6.7% | 0.8% | ||
| Q1 25 | 4.8% | 0.6% | ||
| Q4 24 | 6.5% | — | ||
| Q3 24 | 7.7% | 0.7% | ||
| Q2 24 | 8.4% | 1.6% | ||
| Q1 24 | 8.2% | 0.7% |
现金转化率STETRMB
| Q4 25 | 1.55× | — | ||
| Q3 25 | 1.50× | 1.39× | ||
| Q2 25 | 2.37× | 2.33× | ||
| Q1 25 | 1.79× | 1.28× | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.67× | 2.34× | ||
| Q2 24 | 2.09× | 0.07× | ||
| Q1 24 | — | 4.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
TRMB
| Subscription and services | $701.5M | 72% |
| Product | $268.3M | 28% |
